Scientists Develop First Human Monoclonal Antibody to Block Epstein-Barr Virus Infection
Fred Hutch Cancer Center breakthrough offers new hope against EBV-linked cancers and transplant complications
Few viruses are as widespread or as underestimated as the Epstein-Barr virus (EBV). Commonly transmitted through saliva and often dubbed the cause of infectious mononucleosis, EBV is far more than a transient rite of passage in adolescence. It is estimated to infect approximately 95% of the global population, establishing lifelong latency after primary infection.
